Chitosan-DNA nanoparticles/siRNA targeting CCR2 (CNP/siCCR2) nanoparticles inhibit TAM recruitment, reduce tumor immunosuppression, and enhance chemotherapy efficacy in BC models (70). This evidence concerns the gene CCR2 and neoplasm.